Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : RVNC source : Www.biospace.com save search
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.17%
H: 0.17%
C: -1.9%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -2.01%
H: 1.37%
C: -5.92%
daxxify neurology meeting
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Published: 2024-03-04 (Crawled : 17:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 0.08%
C: -1.83%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -11.6%
H: 3.89%
C: -1.62%
million offering
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.15%
H: 0.76%
C: 0.3%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.18%
H: 0.72%
C: -2.72%
year financial results
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Published: 2024-02-01 (Crawled : 21:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.42%
H: 1.75%
C: 1.28%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 1.59%
H: 4.11%
C: 0.78%
conference
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Published: 2024-01-08 (Crawled : 14:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.83%
H: 0.72%
C: -1.43%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -13.17%
H: 3.45%
C: -2.76%
year financial
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Published: 2023-11-01 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.45%
H: 0.96%
C: 0.68%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -0.63%
H: 1.66%
C: 1.15%
financial results
Revance to Host Investor Day on September 19, 2023
Published: 2023-08-22 (Crawled : 14:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.18%
H: 0.45%
C: -0.62%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.28%
H: 2.33%
C: 1.65%
day
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -1.06%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 6.13%
H: 1.54%
C: -3.04%
daxxify fda treatment injection
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Published: 2023-08-01 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.19%
H: 0.29%
C: -2.76%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
financial results
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Published: 2023-05-02 (Crawled : 12:20) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.21%
H: 0.21%
C: -2.36%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.65%
H: 2.62%
C: 1.97%
financial results
Revance to Participate in Upcoming Investor Conferences - March 7, 2023
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.09%
H: 0.18%
C: -1.29%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.36%
H: 0.69%
C: -0.6%
Revance to Participate in the 43rd Annual Cowen Healthcare Conference
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -1.13%
H: 3.69%
C: -1.58%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.79%
H: 3.84%
C: 2.06%
conference
Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.44%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.48%
H: 4.73%
C: 2.5%
daxxify treatment meeting association injection
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-01-09 (Crawled : 19:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.17%
H: 0.58%
C: -0.91%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 15.12%
H: 34.86%
C: 34.07%
daxxify commercial year financial update results
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
Published: 2022-11-22 (Crawled : 14:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -1.35%
H: 1.46%
C: 1.19%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -0.14%
H: 3.44%
C: 2.76%
conference
Nanostics Announces New Member of Board of Directors
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -1.81%
H: 0.88%
C: -3.34%
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
Published: 2022-11-04 (Crawled : 13:20) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 1.44%
H: 0.0%
C: -2.93%
aesthetic injection
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Published: 2022-11-01 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.59%
H: 1.18%
C: 0.59%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 0.85%
H: 1.73%
C: -0.18%
financial results
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2022-10-20 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.11%
H: 1.17%
C: -0.53%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: -0.04%
H: 3.56%
C: -1.55%
treatment application license injection
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
Published: 2022-10-17 (Crawled : 15:20) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 1.05%
H: 0.62%
C: -0.41%
RVNC | $3.77 -0.53% -0.53% 1.6M
|
Health Technology
|
| O: 1.59%
H: 1.57%
C: -3.33%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.